Santen's main office is located in Kita Ward, Osaka City, Osaka Prefecture and 3 factories are in Ishikawa, Shiga and Nara Research and Development Center in Nara Prefecture.

Santen's 21 subsidiaries are located in the following countries: Japan, United States, Netherlands, Finland, United Kingdom, Spain, Switzerland, Italy, France, Germany, Sweden, China, Korea , Taiwan, India, Thailand, Malaysia, Philippines and Singapore.

The company's milestones:

- In 1890: Kenkichi Taguchi opened Taguchi Santendo pharmacy at 1- chome Kitahama, Higashi-ku (now Chuo-ku), Osaka-shi, Osaka. Santen’s main product at the time of establishment was a cold medication called Heburin-gan.

- In 1899: Launched Daigaku brand eye drops.

- In 1925: Santendo Co., Ltd. established.

- In 1935: Opening of Yodogawa Factory (later headquarters) in Shimoshinjo-cho, Higashiyodogawa-ku, Osaka.

- In 1945: Company name changed to Santendo Pharmaceutical Co., Ltd..

- In 1958: Company renamed as Santen Pharmaceutical Co., Ltd. (current name).

- In 1962: Launched Japan’s first plastic eye drop container (Super Sante).

- In 1963:Thiola, an original antidote for liver treatment, launched in Japan.

- In 1965:Sante de U launched in Japan.

- In 1970: Antibiotic ophthalmic Ecolicin launched in Japan.

- In 1975: Anti-inflammatory ophthalmic Flumetholon launched in Japan.

- In 1977: Santen introduces a “bottle pack” production system, developed by Rommelag, a West German company. This enables container molding and solution filling in a single step. Santen thus becomes the first company to produce bottle-packed eye drops in Japan.

- In 1978: Santen begins marketing medical devices with the electroretinograph ROX-5T, produced by Heiwa Electric Industrial Co., Ltd. .

- In 1981:Timoptol, a treatment for glaucoma and ocular hypertension, launched in Japan.

- In 1982: Central Research Laboratories opened in Osaka.

- In 1985: Noto Plant opened and launched Sante 40 NE, an over-the-counter eye lotion for the treatment of blurred vision and eyestrain..

- In 1987: Anti-infective ophthalmic Tarivid launched in Japan.

- In 1992: Tahmin Santen Co., Ltd. established in Taiwan. Kary Uni, a treatment for early-stage senile cataracts, launched in Japan.

- In 1993: Subsidiary Santen Inc. established in the U.S.

- In 1994: Subsidiary Santen GmbH established in Germany

- In 1996: Opened Beijing Representative Office, Nara Research and Development Center and Shiga Plant.

- In 1997: Santen acquired Oy Star Ab, a Finnish ophthalmic pharmaceutical company, and establishes Santen Oy, the first overseas production base for Santen

- In 1999:Timoptol XE, a treatment for glaucoma and ocular hypertension, launched in Japan.

- In 2000: Santen Pharmaceutical Korea, Co., Ltd. and Guangzhou Representative Office established.

- In 2001: Santen acquired the U.S. firm Advanced Vision Science, Inc.

- In 2002: Sante de U plus E alfa, Sante 40V và Sante 40  launched in Japan.

- In 2004: U.S. sales partnership with Johnson & Johnson Vision Care, Inc. (currently VISTAKON pharmaceuticals, LLC) started.

- In 2005: Santen Pharmaceutical (China) Co., Ltd. established.

-  In 2007: Suzhou Plant established in China. Sante Uruoi Contact a launched in Japan.

- In 2010:Diquas is the world’s first eye drop to take advantage of the pharmacological action of a P2Y2 receptor agonist, launched.

- In 2013: Ho Chi Minh Representative Office established.

- In 2014: Established subsidiaries in Switzerland, Italy, the U.K., Spain, Thailand, Malaysia and the Philippines. Launch of TAPCOM (tafluprost/timolol maleate), a treatment for glaucoma and ocular hypertension.

- In 2016: Established Santen Business Services Co., Ltd., Santen Eye Care Co., Ltd., Santen Pharmaceutical (Hong Kong) Limited.

- In 2017: Santen Limited Liability Company in Russia established.

- In 2019: Santen Canada Inc. in Canada established.

- In 2020: Entered into an Exclusive Licensing Contract with jCyte in Japan, Asia and Europe for the jCell Therapy Program for Retinitis Pigmentosa.

- In 2022:DIQUAS LX Ophthalmic Solution 3% for dry-eye treatment dry-eye treatment launched in Japan.

- In 2023:Sante Medical Plus series launched in Japan.

According to santen.com, ja.wikipedia.org